Abbott Laboratories
Delaware, United States · Biotechnology, Health Care, Manufacturing
Abbott Laboratories is a global healthcare company that develops and manufactures a wide range of health care products. The company focuses on diagnostics, medical devices, nutrition, and branded generic pharmaceuticals. With a rich history of innovation, Abbott aims to improve lives through its diverse healthcare solutions.
Key facts
- Headquarters
- Delaware, United States
- Employees
- 115,000
- Industries
- Biotechnology, Health Care, Manufacturing
- Status
- Public (ABT)
- Website
- abbott.com
- Company page
Recent activity at Abbott Laboratories
- : SEC 8-K (8.01): Abbott Laboratories announced a significant strategic move to separate its global nutrition business into an independent, publicly traded company. This decision was detailed in a press release dated October 21, 2026, and is expected to create further value for shareholders by allowing the new entity to focus solely on the nutrition sector. The separation represents a noteworthy shift in Abbott's business model, aiming to enhance operational efficiencies and market positioning for both Abbott and the newly formed company. The exact financial implications and terms of the transaction are not disclosed in the filing, but the move underscores Abbott's commitment to streamline its operations.
- : Abbott Laboratories Forms Exclusive Partnership with Berry Street for Lingo Nutritional Coaching.
- : SEC 8-K (7.01): On August 20, 2026, Abbott Laboratories announced the settlement of a portion of its litigation concerning its specialty formulas for preterm infants. This settlement represents a significant development for the company amidst ongoing legal challenges. The details of the settlement, including financial implications or specific terms, were provided in the press release attached as Exhibit 99.1. The resolution of this litigation is expected to enhance Abbott's operational focus and reduce uncertainties regarding its product lines.
- : SEC 8-K (5.02): On April 24, 2026, Kevin Conroy was appointed to Abbott Laboratories' Board of Directors. Additionally, at the same date, Abbott shareholders approved the adoption of the 2026 Incentive Stock Program, which replaces the previous 2017 Program. The new program allows for the issuance of up to 140,000,000 shares with various performance-based awards to be granted, demonstrating Abbott's strategic move to enhance its equity-related incentives for its workforce. The program has a term of ten years and is intended to align the interests of shareholders and employees more closely.
- : SEC 8-K (8.01):
- : SEC 8-K (2.02): On April 16, 2026, Abbott Laboratories reported its financial results for the first quarter of 2026. The announcement included various non-GAAP financial measures, such as net earnings excluding specified items related to acquisitions and stock-based compensation. The results are provided in their news release, which is attached as Exhibit 99.1. This filing indicates strategic financial adjustments which could impact investors and stakeholders, particularly in light of expenses linked to acquisitions and restructuring actions.
- : SEC 8-K (8.01): On March 23, 2026, Abbott Laboratories completed the acquisition of Exact Sciences Corporation through a merger agreement dated November 19, 2025. The merger involved Abbott’s subsidiary, Badger Merger Sub I, Inc., merging with Exact Sciences, resulting in Exact becoming a wholly owned subsidiary of Abbott. At the effective time of the merger, shareholders of Exact Sciences received $105.00 in cash per share, excluding certain shares and subject to withholding taxes. This acquisition is expected to strengthen Abbott's portfolio in the diagnostics sector, underscoring its strategic expansion into cancer screening and diagnostics.
- : SEC 8-K (1.01): On March 9, 2026, Abbott Laboratories entered into a material definitive agreement for the public offering and issuance of senior notes totaling $20,000,000,000 in aggregate principal. This issuance included various tranches: $1,000,000,000 in Floating Rate Notes due 2029, $2,250,000,000 in 3.700% Notes due 2029, $2,500,000,000 in 4.000% Notes due 2031, and $2,750,000,000 in 4.300% Notes due 2033. This significant capital raising effort aims to enhance Abbott's financial position and provide liquidity for corporate purposes, which may include funding ongoing operations and growth initiatives.
- : SEC 8-K (1.01): On March 9, 2026, Abbott Laboratories entered into a material definitive agreement by completing a public offering of $20 billion in senior notes to fund the acquisition of Exact Sciences Corporation. This offering includes various series of notes with varying due dates and interest rates, all planned to provide funds for the Exact Sciences Acquisition, which was structured under an Agreement and Plan of Merger dated November 19, 2025. The transaction is contingent on the successful closure of the acquisition by a specified date and involves complexities such as funding the acquisition costs and repaying Exact Sciences' indebtedness. The financing arrangement also outlines conditions for termination if the acquisition is not completed by the agreed deadline, or if Abbott decides not to proceed with the acquisition.
- : Abbott Laboratories to acquire Exact Sciences
Leadership
- Alaa Samara, Director MA
- Aquil Naqvi, Global Business HR Director
- Pooja Rao, Talent Acquisition Director, India Region
- Vikas Shukla, Senior Data Engineer
- David Cartwright, Senior Recruiter
- Jonas Sagadraca, Head of PH Operations | Acelis Connected Health - Abbott HF
- Yakub Khan, Regional Procurement Manager (Head of Department)Global Procurement
- Melina Grippo, Talent Acquisition Manager - South Cone
- Thais Camargo, Especialista em Aquisição de Talentos
- Vikas Shukla, Senior Data Engineer
- Premnath Unnikrishnan, Head Of Digital Marketing
Verified email and direct lines for Abbott Laboratories’s decision-makers are on Fundz. See plans — or book a 15-minute walkthrough.
Employee benefit plans
Abbott Laboratories files 25 employee benefit plans with the U.S. Department of Labor, including a retirement plan. The next plan year renews in Dec 2026.
Abbott Laboratories in the news
- Q1 progress positions Abbott for 2026 growth | Abbott Newsroom - Abbott (Apr 17, 2026)
- Abbott statement on cyber incident in Cancer Diagnostics business - Abbott (Jul 16, 2026)
- How tech is transforming healthcare - Abbott (Mar 10, 2026)
- Abbott 2025 Results: Double?Digit Earnings Growth | Abbott Newsroom - Abbott (Jan 23, 2026)
- Abbott Update On Powder Formula Recall | Abbott Newsroom - Abbott (Dec 12, 2025)
- Partnering Across Asia - Abbott (Dec 12, 2025)
- Abbott receives FDA authorization for world's first dual glucose-ketone sensing technology for people with diabetes - Abbott MediaRoom (Aug 25, 2026)
- Putting high-risk (HR) HPV to the test: A new generation of testing - Abbott (Dec 08, 2025)
Companies similar to Abbott Laboratories
- Becton Dickinson · Biotechnology, Health Care, Manufacturing, Medical, Medical Device
- IEC Medical Systems · Biotechnology, Health Care, Manufacturing, Medical, Medical Device
- Boston Scientific · Biotechnology, Health Care, Manufacturing, Medical, Medical Device
- Baxter International · Biotechnology, Health Care, Manufacturing, Medical, Medical Device
- Alcon Silver · Biotechnology, Health Care, Manufacturing, Medical, Medical Device
About Abbott Laboratories: questions and answers
What does Abbott Laboratories do?
Abbott Laboratories is a global healthcare company that develops and manufactures a wide range of health care products. The company focuses on diagnostics, medical devices, nutrition, and branded generic pharmaceuticals. With a rich history of innovation, Abbott aims to improve lives through its diverse healthcare solutions.
Where is Abbott Laboratories headquartered?
Abbott Laboratories is headquartered in Delaware, United States.
How many employees does Abbott Laboratories have?
Abbott Laboratories has about 115,000 employees.
What is the latest news on Abbott Laboratories?
On Oct 21, 2026, SEC 8-K (8.01): Abbott Laboratories announced a significant strategic move to separate its global nutrition business into an independent, publicly traded company. This decision was detailed in a press release dated October 21, 2026, and is expected to create further value for shareholders by allowin
Is Abbott Laboratories a public company?
Yes. Abbott Laboratories is publicly traded under the ticker ABT.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy